1. Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer. BMC Gastroenterol. 2017 Nov 23;17(1):121
2. HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF. Clin Colorectal Cancer. 2017 Sep;16(3):e147-e152.
3. Use of a High-throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer.
Cancer Res Treat. 2017 Jan;49(1):37-43
4. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab. Ann Hematol. 2014 Oct;93(10):1755-64
5. Inflammatory Myofibroblastic Tumor Showing Durable Remission after Anthracycline-Containing Cytotoxic Chemotherapy: Report of a Case. Korean J Med 2012;82(6):749-753.
<학회발표>
1. High-throughput mutation extended RAS genotyping (OncoMap) to predict the efficacy of cetuximab treatment in metastastic colorectal cancer. 한국임상암학회 2015
2. Right-sided colon cancer is associated with poor efficacy of cetuximab in patients with RAS wild-type metastatic colorectal cancer. American Society of Clinical Oncology Annual Meeting 2016
Analysis of Cancer Patient Decision-Making and Health Service Utilization after Enforcement of the Life-Sustaining Treatment Decision-Making Act in Korea
Cancer Res Treat. 2022;54(1):20-29
BAP1 Downregulates NRF2 Target Genes and Exerts Anti-Tumorigenic Effects by Deubiquitinating KEAP1 in Lung Adenocarcinoma
Antioxidants 2022, 11, 114.
Consistent Response on Challenge and Rechallenge of Liposomal Irinotecan in a Patient with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine plus Nab-Paclitaxel: A Case Report
Case Rep Oncol 2021;14:1882–1888
Incidence and Clinical Outcomes of Febrile Neutropenia in Adult Cancer Patients with Chemotherapy Using Korean Nationwide Health Insurance Database
Yonsei Med J 2021 Jun;62(6):479-486
2020 Korean guidelines for the management of metastatic prostate cancer
Korean J Intern Med 2021;36:491-514
The efficacy and safety of onartuzumab in patients with solid cancers: A meta‑analysis of randomized trials
